Elly L van der Veen1, Frans V Suurs1, Frederik Cleeren2, Guy Bormans2, Philip H Elsinga3, Geke A P Hospers1, Marjolijn N Lub-de Hooge3,4, Elisabeth G E de Vries1, Erik F J de Vries3, Inês F Antunes5. 1. Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 2. Laboratory for Radiopharmaceutical Research, Department of Pharmacy and Pharmacology, University of Leuven, Leuven, Belgium. 3. Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; and. 4. Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 5. Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; and i.farinha.antunes@umcg.nl.
Abstract
Recently, N-(4-18F-fluorobenzoyl)-interleukin-2 (18F-FB-IL2) was introduced as a PET tracer for T cell imaging. However, production is complex and time-consuming. Therefore, we developed 2 radiolabeled IL2 variants, namely aluminum 18F-fluoride-(restrained complexing agent)-IL2 (18F-AlF-RESCA-IL2) and 68Ga-gallium-(1,4,7-triazacyclononane-4,7-diacetic acid-1-glutaric acid)-IL2 (68Ga-Ga-NODAGA-IL2), and compared their in vitro and in vivo characteristics with 18F-FB-IL2. Methods: Radiolabeling of 18F-AlF-RESCA-IL2 and 68Ga-Ga-NODAGA-IL2 was optimized, and stability was evaluated in human serum. Receptor binding was studied with activated human peripheral blood mononuclear cells (hPBMCs). Ex vivo tracer biodistribution in immunocompetent BALB/cOlaHsd (BALB/c) mice was performed at 15, 60, and 90 min after tracer injection. In vivo binding characteristics were studied in severe combined immunodeficient (SCID) mice inoculated with activated hPBMCs in Matrigel. Tracer was injected 15 min after hPBMC inoculation, and a 60-min dynamic PET scan was acquired, followed by ex vivo biodistribution studies. Specific uptake was determined by coinjection of tracer with unlabeled IL2 and by evaluating uptake in a control group inoculated with Matrigel only. Results: 68Ga-Ga-NODAGA-IL2 and 18F-AlF-RESCA-IL2 were produced with radiochemical purity of more than 95% and radiochemical yield of 13.1% ± 4.7% and 2.4% ± 1.6% within 60 and 90 min, respectively. Both tracers were stable in serum, with more than 90% being intact tracer after 1 h. In vitro, both tracers displayed preferential binding to activated hPBMCs. Ex vivo biodistribution studies on BALB/c mice showed higher uptake of 18F-AlF-RESCA-IL2 than of 18F-FB-IL2 in liver, kidney, spleen, bone, and bone marrow. 68Ga-Ga-NODAGA-IL2 uptake in liver and kidney was higher than 18F-FB-IL2 uptake. In vivo, all tracers revealed uptake in activated hPBMCs in SCID mice. Low uptake was seen after a blocking dose of IL2 and in the Matrigel control group. In addition, 18F-AlF-RESCA-IL2 yielded the highest-contrast PET images of target lymph nodes. Conclusion: Production of 18F-AlF-RESCA-IL2 and 68Ga-Ga-NODAGA-IL2 is simpler and faster than that of 18F-FB-IL2. Both tracers showed good in vitro and in vivo characteristics, with high uptake in lymphoid tissue and hPBMC xenografts.
Recently, N-(4-18F-fluorobenzoyl)-interleukin-2 (18F-FB-IL2) was introduced as a PET tracer for T cell imaging. However, production is complex and time-consuming. Therefore, we developed 2 radiolabeled IL2 variants, namely aluminum 18F-fluoride-(restrained complexing agent)-IL2 (18F-AlF-RESCA-IL2) and 68Ga-gallium-(1,4,7-triazacyclononane-4,7-diacetic acid-1-glutaric acid)-IL2 (68Ga-Ga-NODAGA-IL2), and compared their in vitro and in vivo characteristics with 18F-FB-IL2. Methods: Radiolabeling of 18F-AlF-RESCA-IL2 and 68Ga-Ga-NODAGA-IL2 was optimized, and stability was evaluated in human serum. Receptor binding was studied with activated human peripheral blood mononuclear cells (hPBMCs). Ex vivo tracer biodistribution in immunocompetent BALB/cOlaHsd (BALB/c) mice was performed at 15, 60, and 90 min after tracer injection. In vivo binding characteristics were studied in severe combined immunodeficient (SCID) mice inoculated with activated hPBMCs in Matrigel. Tracer was injected 15 min after hPBMC inoculation, and a 60-min dynamic PET scan was acquired, followed by ex vivo biodistribution studies. Specific uptake was determined by coinjection of tracer with unlabeled IL2 and by evaluating uptake in a control group inoculated with Matrigel only. Results: 68Ga-Ga-NODAGA-IL2 and 18F-AlF-RESCA-IL2 were produced with radiochemical purity of more than 95% and radiochemical yield of 13.1% ± 4.7% and 2.4% ± 1.6% within 60 and 90 min, respectively. Both tracers were stable in serum, with more than 90% being intact tracer after 1 h. In vitro, both tracers displayed preferential binding to activated hPBMCs. Ex vivo biodistribution studies on BALB/c mice showed higher uptake of 18F-AlF-RESCA-IL2 than of 18F-FB-IL2 in liver, kidney, spleen, bone, and bone marrow. 68Ga-Ga-NODAGA-IL2 uptake in liver and kidney was higher than 18F-FB-IL2 uptake. In vivo, all tracers revealed uptake in activated hPBMCs in SCID mice. Low uptake was seen after a blocking dose of IL2 and in the Matrigel control group. In addition, 18F-AlF-RESCA-IL2 yielded the highest-contrast PET images of target lymph nodes. Conclusion: Production of 18F-AlF-RESCA-IL2 and 68Ga-Ga-NODAGA-IL2 is simpler and faster than that of 18F-FB-IL2. Both tracers showed good in vitro and in vivo characteristics, with high uptake in lymphoid tissue and hPBMC xenografts.
Authors: Urszula Karczmarczyk; Piotr Garnuszek; Michał Maurin; Valentina Di Gialleonardo; Filippo Galli; Alberto Signore; Renata Mikołajczak Journal: Nucl Med Biol Date: 2010-10 Impact factor: 2.408
Authors: S V Hartimath; O Draghiciu; S van de Wall; V Manuelli; R A J O Dierckx; H W Nijman; T Daemen; E F J de Vries Journal: Oncoimmunology Date: 2016-11-18 Impact factor: 8.110
Authors: Klaus-Peter Eisenwiener; M I M Prata; I Buschmann; Han-Wen Zhang; A C Santos; Sandra Wenger; Jean Claude Reubi; Helmut R Mäcke Journal: Bioconjug Chem Date: 2002 May-Jun Impact factor: 4.774
Authors: Richard Tavaré; Melissa N McCracken; Kirstin A Zettlitz; Felix B Salazar; Tove Olafsen; Owen N Witte; Anna M Wu Journal: J Nucl Med Date: 2015-05-07 Impact factor: 10.057
Authors: Wouter B Nagengast; Elisabeth G de Vries; Geke A Hospers; Nanno H Mulder; Johan R de Jong; Harry Hollema; Adrienne H Brouwers; Guus A van Dongen; Lars R Perk; Marjolijn N Lub-de Hooge Journal: J Nucl Med Date: 2007-07-13 Impact factor: 10.057
Authors: Mohammad Rashidian; Jessica R Ingram; Michael Dougan; Anushka Dongre; Katherine A Whang; Camille LeGall; Juan J Cragnolini; Brian Bierie; Monica Gostissa; James Gorman; Gijsbert M Grotenbreg; Atul Bhan; Robert A Weinberg; Hidde L Ploegh Journal: J Exp Med Date: 2017-06-30 Impact factor: 14.307
Authors: Svetomir N Markovic; Filippo Galli; Vera J Suman; Wendy K Nevala; Andrew M Paulsen; Joseph C Hung; Denise N Gansen; Lori A Erickson; Paolo Marchetti; Gregory A Wiseman; Alberto Signore Journal: Oncotarget Date: 2018-07-13
Authors: Elly L van der Veen; Inês F Antunes; Petra Maarsingh; Janet Hessels-Scheper; Rolf Zijlma; Hendrikus H Boersma; Annelies Jorritsma-Smit; Geke A P Hospers; Elisabeth G E de Vries; Marjolijn N Lub-de Hooge; Erik F J de Vries Journal: EJNMMI Radiopharm Chem Date: 2019-07-17
Authors: Kornelis S M van der Geest; Maria Sandovici; Pieter H Nienhuis; Riemer H J A Slart; Peter Heeringa; Elisabeth Brouwer; William F Jiemy Journal: Front Med (Lausanne) Date: 2022-06-06
Authors: Omar Abousaway; Taha Rakhshandehroo; Annick D Van den Abbeele; Moritz F Kircher; Mohammad Rashidian Journal: Nanotheranostics Date: 2021-01-01
Authors: Dario Gosmann; Lisa Russelli; Angela M Krackhardt; Calogero D'Alessandria; Wolfgang A Weber; Markus Schwaiger Journal: EJNMMI Res Date: 2022-01-31 Impact factor: 3.138
Authors: Kevin P Maresca; Jianqing Chen; Divya Mathur; Anand Giddabasappa; Adam Root; Jatin Narula; Lindsay King; David Schaer; Jonathan Golas; Keith Kobylarz; Edward Rosfjord; Edmund Keliher; Laigao Chen; Sripad Ram; Eve H Pickering; James S Hardwick; Paul A Rejto; Amira Hussein; Ohad Ilovich; Kevin Staton; Ian Wilson; Timothy J McCarthy Journal: Mol Imaging Biol Date: 2021-06-18 Impact factor: 3.488